PortfoliosLab logoPortfoliosLab logo
SYRE vs. MSTR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SYRE vs. MSTR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spyre Therapeutics Inc. (SYRE) and Strategy Inc (MSTR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SYRE achieves a 111.11% return, which is significantly higher than MSTR's -10.44% return. Over the past 10 years, SYRE has underperformed MSTR with an annualized return of -9.61%, while MSTR has yielded a comparatively higher 21.84% annualized return.


SYRE

1D
-1.96%
1M
-0.37%
YTD
111.11%
6M
143.52%
1Y
349.09%
3Y*
178.55%
5Y*
-16.21%
10Y*
-9.61%

MSTR

1D
-9.15%
1M
-23.19%
YTD
-10.44%
6M
-24.95%
1Y
-63.45%
3Y*
65.15%
5Y*
22.73%
10Y*
21.84%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SYRE vs. MSTR - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SYRE
Spyre Therapeutics Inc.
111.11%40.72%8.18%91.33%-90.53%-39.64%3.01%2.00%38.45%24.37%
MSTR
Strategy Inc
-10.44%-47.53%358.54%346.15%-74.00%40.13%172.42%11.65%-2.70%-33.49%

Correlation

The correlation between SYRE and MSTR is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (10Y)
Calculated over the trailing 10-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Apr 8, 2016

0.20

Fundamentals

Market Cap

SYRE:

$23.93B

MSTR:

$45.44B

EPS

SYRE:

-$0.88

MSTR:

-$40.19

PS Ratio

SYRE:

155.37

MSTR:

85.31

PB Ratio

SYRE:

45.64

MSTR:

1.24

Total Revenue (TTM)

SYRE:

$90.49M

MSTR:

$490.47M

Gross Profit (TTM)

SYRE:

$0.00

MSTR:

$334.08M

EBITDA (TTM)

SYRE:

-$171.29M

MSTR:

$466.93M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SYRE vs. MSTR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYRE
SYRE Risk / Return Rank: 9898
Overall Rank
SYRE Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
SYRE Sortino Ratio Rank: 9797
Sortino Ratio Rank
SYRE Omega Ratio Rank: 9595
Omega Ratio Rank
SYRE Calmar Ratio Rank: 9999
Calmar Ratio Rank
SYRE Martin Ratio Rank: 9999
Martin Ratio Rank

MSTR
MSTR Risk / Return Rank: 88
Overall Rank
MSTR Sharpe Ratio Rank: 66
Sharpe Ratio Rank
MSTR Sortino Ratio Rank: 55
Sortino Ratio Rank
MSTR Omega Ratio Rank: 77
Omega Ratio Rank
MSTR Calmar Ratio Rank: 99
Calmar Ratio Rank
MSTR Martin Ratio Rank: 1212
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SYRE vs. MSTR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and Strategy Inc (MSTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SYREMSTRDifference

Sharpe ratio

Return per unit of total volatility

5.18

-0.91

+6.09

Sortino ratio

Return per unit of downside risk

4.87

-1.55

+6.42

Omega ratio

Gain probability vs. loss probability

1.58

0.83

+0.75

Calmar ratio

Return relative to maximum drawdown

16.87

-0.82

+17.69

Martin ratio

Return relative to average drawdown

41.14

-1.23

+42.37

SYRE vs. MSTR - Sharpe Ratio Comparison

The current SYRE Sharpe Ratio is 5.18, which is higher than the MSTR Sharpe Ratio of -0.91. The chart below compares the historical Sharpe Ratios of SYRE and MSTR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SYREMSTRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

5.18

-0.91

+6.09

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.09

0.25

-0.34

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.07

0.30

-0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.09

0.13

-0.21

Drawdowns

SYRE vs. MSTR - Drawdown Comparison

The maximum SYRE drawdown since its inception was -99.11%, roughly equal to the maximum MSTR drawdown of -99.86%. Use the drawdown chart below to compare losses from any high point for SYRE and MSTR.


Loading charts...

Drawdown Indicators


SYREMSTRDifference

Max Drawdown

Largest peak-to-trough decline

-99.11%

-99.86%

+0.75%

Max Drawdown (1Y)

Largest decline over 1 year

-20.91%

-76.53%

+55.62%

Max Drawdown (3Y)

Largest decline over 3 years

-73.99%

-77.42%

+3.43%

Max Drawdown (5Y)

Largest decline over 5 years

-98.74%

-84.11%

-14.63%

Max Drawdown (10Y)

Largest decline over 10 years

-99.04%

-89.27%

-9.77%

Current Drawdown

Current decline from peak

-76.93%

-71.28%

-5.65%

Average Drawdown

Average peak-to-trough decline

-62.66%

-86.48%

+23.82%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.57%

51.39%

-42.82%

Volatility

SYRE vs. MSTR - Volatility Comparison

The current volatility for Spyre Therapeutics Inc. (SYRE) is 14.50%, while Strategy Inc (MSTR) has a volatility of 19.27%. This indicates that SYRE experiences smaller price fluctuations and is considered to be less risky than MSTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SYREMSTRDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.50%

19.27%

-4.77%

Volatility (6M)

Calculated over the trailing 6-month period

45.83%

56.14%

-10.31%

Volatility (1Y)

Calculated over the trailing 1-year period

67.95%

69.99%

-2.04%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

178.98%

90.74%

+88.24%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

136.30%

73.68%

+62.62%

Dividends

SYRE vs. MSTR - Dividend Comparison

Neither SYRE nor MSTR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

SYRE vs. MSTR - Financials Comparison

This section allows you to compare key financial metrics between Spyre Therapeutics Inc. and Strategy Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M140.00M202220232024202520260
124.30M
(SYRE) Total Revenue
(MSTR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


SYRE and MSTR have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MSTR has higher volatility (19.27%) compared to SYRE (14.50%). In terms of maximum drawdown, SYRE dropped -99.11% vs MSTR's -99.86%.

SYRE currently has the higher Sharpe Ratio (5.18 vs -0.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SYRE and MSTR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer